HLA-Resolve workflow validated for high-resolution HLA typing in 32 diverse samples

This methodological validation study assessed the HLA-Resolve workflow, which uses multiplexed long-read hybrid capture for PacBio and Oxford Nanopore sequencing paired with the HLA-Resolve typing program. The study evaluated 32 geographically diverse samples against established benchmarks from the Genome in a Bottle, Human Pangenome Reference Consortium, and International Histocompatibility Working Group. The primary outcome was workflow performance, which was reported as validated against these benchmarks, though specific effect sizes, absolute numbers, and statistical measures were not reported.

Safety and tolerability data were not reported, as this was a bench methodology study rather than a clinical trial. The study did not report on adverse events, serious adverse events, or discontinuations.

Key limitations include the absence of reported statistical validation metrics, the small sample size of 32 samples, and the lack of direct clinical outcome correlation. The study phase, follow-up duration, and funding/conflict disclosures were also not reported.

The authors suggest this workflow offers a cost-effective approach for high-resolution HLA typing with potential clinical applicability and enables investigation of HLA Class III variation in disease. However, this represents a technical validation that requires further clinical studies to establish diagnostic accuracy, clinical utility, and implementation feasibility in patient care settings.